Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored Treatment of Metastatic Colorectal Cancer Based on Genetic Markers
NCT00396487Phase 3Terminated
- Sponsor
- Vejle Hospital
- Start
- Nov 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fluorouracil, capecitabine and irinotecan in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Vejle Hospital. Primary endpoint: Objective Response Rate. Started Nov 2006; status: terminated.
02
Drugs
fluorouracilcapecitabineirinotecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00396487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396487.